At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 120 enrolled
Drug / intervention
pGA2/JS7 DNA +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA Vaccine and Recombinant Modified Vaccinia Ankara/HIV62 Vaccine in Healthy, HIV-1-Uninfected Adult Participants
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Mar 10, 2006·Updated Aug 8, 2022
In Brief
A Phase 1 clinical trial evaluating pGA2/JS7 DNA and Modified vaccinia Ankara/HIV62 for HIV Infections. Completed, enrolled 120 participants across 6 sites.
Detailed Summary
The purpose of this study is to determine the safety of and immune response to a DNA HIV vaccine, pGA2/JS7, followed by a modified vaccinia (smallpox) HIV vaccine, MVA/HIV62, in HIV uninfected adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsHIV Vaccine Trials Network
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2006
Enrollment StartApr 2006
Study CompletionDec 2008
TodayJul 2026
First PostedMar 10, 2006
Enrollment StartApr 1, 2006
Study CompletionDec 1, 2008
TodayJul 2, 2026
Posted 20.3 years ago
Interventions
pGA2/JS7 DNAbiological
DNA Vaccine
Modified vaccinia Ankara/HIV62biological
Recombinant Modified Ankara Vaccine